sur Kinarus Therapeutics Holding AG (isin : CH0009115129)
Kinarus Therapeutics Holding Announces Positive Outcome from Extraordinary General Meeting with Curatis
Basel, March 1, 2024 – Kinarus Therapeutics Holding AG (SIX: KNRS), a Swiss Exchange-listed company specializing in the development of therapeutic drugs, has successfully gained the approval of its shareholders for all resolutions concerning its business combination with Curatis AG. The Extraordinary General Meeting, which took place today, saw sweeping majorities in favor of the merger with Curatis, a company based in Basel-Landschaft focusing on orphan/ultra-orphan and specialty care diseases.
The transaction is anticipated to finalize by the end of April 2024, pending the satisfaction of certain conditions in addition to the shareholder approval already received. This strategic move is expected to bolster Kinarus Holding's position in the market by combining its expertise with Curatis’s specialization in niche disease fields.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Kinarus Therapeutics Holding AG